Imaging and in vivo quantitation of β-amyloid:: An exemplary biomarker for Alzheimer's disease?

被引：23

作者：

Nichols, Lisa ^{[1
]}

Pike, Victor W. ^{[1
]}

Cai, Lisheng ^{[1
]}

Innis, Robert B. ^{[1
]}

机构：

[1] NIMH, Mol Imaging Branch, Bethesda, MD 20892 USA

来源：

BIOLOGICAL PSYCHIATRY | 2006年 / 59卷 / 10期

关键词：

Alzheimer's disease; imaging; amyloid; biomarker; PET; MRI;

D O I：

10.1016/j.biopsych.2005.12.004

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in the brain. A substantial body of research indicates that the presence of increased beta-amyloid peptide (A beta) is neurotoxic and may initiate the further pathology observed in AD, including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration. The use of brain imaging in patients with or at risk for AD has increased our understanding of pathophysiology of the disease and may potentially aid in diagnosis. The development of new therapeutics that reduce A beta in the brain has also indicated a potential use for amyloid imaging in monitoring response to treatment. This review explores the utility of amyloid as a biomarker and the use of positron emission tomography and magnetic resonance imaging in the diagnosis and treatment of AD.

引用

收藏

页码：940 / 947

页数：8

相关论文

共 67 条

[1] Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease [J].

Agdeppa, ED ;

Kepe, V ;

Liu, J ;

Flores-Torres, S ;

Satyamurthy, N ;

Petric, A ;

Cole, GM ;

Small, GW ;

Huang, SC ;

Barrio, JR .

JOURNAL OF NEUROSCIENCE, 2001, 21 (24) :art. no.-RC189

[2] In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile [J].

Agdeppa, ED ;

Kepe, V ;

Petric, A ;

Satyamurthy, N ;

Liu, J ;

Huang, SC ;

Small, GW ;

Cole, GM ;

Barrio, JR .

NEUROSCIENCE, 2003, 117 (03) :723-730

[3] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].

Aisen, PS ;

Schafer, KA ;

Grundman, M ;

Pfeiffer, E ;

Sano, M ;

Davis, KL ;

Farlow, MR ;

Jin, S ;

Thomas, RG ;

Thal, LJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826

[4] The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease [J].

Beffert, U ;

Danik, M ;

Krzywkowski, P ;

Ramassamy, C ;

Berrada, F ;

Poirier, J .

BRAIN RESEARCH REVIEWS, 1998, 27 (02) :119-142

[5] Frequency of stages of Alzheimer-related lesions in different age categories [J].

Braak, H ;

Braak, E .

NEUROBIOLOGY OF AGING, 1997, 18 (04) :351-357

[6] Mild cognitive impairment -: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? [J].

Chételat, G ;

Desgranges, B ;

de la Sayette, V ;

Viader, F ;

Eustache, F ;

Baron, JC .

NEUROLOGY, 2003, 60 (08) :1374-1377

[7] GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES [J].

CORDER, EH ;

SAUNDERS, AM ;

STRITTMATTER, WJ ;

SCHMECHEL, DE ;

GASKELL, PC ;

SMALL, GW ;

ROSES, AD ;

HAINES, JL ;

PERICAKVANCE, MA .

SCIENCE, 1993, 261 (5123) :921-923

[8] IMAGE-ANALYSIS OF BETA-AMYLOID LOAD IN ALZHEIMERS-DISEASE AND RELATION TO DEMENTIA SEVERITY [J].

CUMMINGS, BJ ;

COTMAN, CW .

LANCET, 1995, 346 (8989) :1524-1528

[9] Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease [J].

Dominguez, DI ;

De Strooper, B .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (07) :324-330

[10] Reconstitution of γ-secretase activity [J].

Edbauer, D ;

Winkler, E ;

Regula, JT ;

Pesold, B ;

Steiner, H ;

Haass, C .

NATURE CELL BIOLOGY, 2003, 5 (05) :486-488

← 1 2 3 4 5 6 7 →